WELCOME TO SANARIA

Sanaria is a biotechnology company exclusively dedicated to the production of a vaccine protective against malaria caused by the pathogen Plasmodium falciparum. Sanaria’s vaccine is based on an approach to immunization that has already proven highly protective in humans.
Learn more

Plasmodium falciparum malaria is responsible for more childhood mortality than any other single infectious agent. Sanaria’s vaccine development efforts are focused on African children, the population most urgently in need of protection. Annually, malaria is responsible for more than 100 million cases and 1 million deaths among African infants and children. Globally there are additional unmet medical needs of enormous proportions, and multiple potential markets.
Learn more

Sanaria is a Maryland-based company that is continually seeking motivated staff and investors with a passion to engage in the fight against malaria.
Learn more

Sanaria opens new Clinical Manufacturing Facility.

Learn more

December 2007
Q & A Session with Sanaria: How to bring a malaria vaccine to market? Larta Institute

December 2007
Sanaria CEO, Dr. Stephen L. Hoffman, interviewed on The Pulse

October 2007
Sanaria opens Clinical Manufacturing Facility; Press Release: featured in Reuters

October 2007
Fred Binka (Sanaria Advisory Board Memeber) featured in Newsweek,
"Giving Globally: The Search for Solutions"

July 2007
Sanaria featured in National Geographic magazine, Bedlam in the Blood,
Malaria

June 2007
Sanaria issued U.S. patent

June 2007
Sanaria signs agreement with University of Maryland Biotechnology Institute

May 2007
Sanaria finalizes agreement with Columbia University to develop genetically attenuated malaria sporozoite vaccine

April 2007
Sanaria featured in BBC documentary.

April 2007
Sanaria receives Phase I SBIR grant from NIAID, NIH

November 2006
PATH-Malaria Vaccine Initiative receives $29.3M from the Bill and Melinda Gates Foundation to support Sanaria’s malaria vaccine development efforts.

November 2006
Sanaria CEO receives award for malariology from American Society of Tropical Medicine and Hygiene

October 2006
Sanaria CEO receives honorary doctoral degree from Monmouth University

September 2006
Sanaria receives Phase II SBIR grant from NIAID, NIH

> learn more